Radioactive 'Smart Bomb' targets Hard-to-Treat prostate cancer in first human trial

NCT ID NCT06492122

Recruiting now Disease control Sponsor: Full-Life Technologies UK Limited Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial is testing a new radioactive drug called FL-020 in 50 men with metastatic castration-resistant prostate cancer (mCRPC), a type of prostate cancer that has spread and stopped responding to hormone therapy. The drug is designed to seek out and deliver radiation directly to cancer cells. The main goals are to check safety, find the right dose, and see early signs of whether it can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A radioactive drug called FL-020 (attached to actinium-225) given by IV
What this could lead to: If it works, this could point toward a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong: This is a very early, small phase 1 trial with only 50 participants, so safety and dosing are still being figured out. The radioactive drug may cause side effects, and there is no guarantee it will shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Ankara Üniversitesi Tıp Fakültesi Cebeci Hastanesi Nükleer Tıp Anabilim Dalı
RECRUITING

Ankara, 06590, Turkey (Türkiye)
Beijing Cancer Hospital
RECRUITING

Beijing, 100142, China
Chao Family Comprehensive Cancer Center
RECRUITING

Irvine, California, 92612, United States
City of Hope Medical Center
RECRUITING

Duarte, California, 91010, United States
Genesiscare Murdoch
RECRUITING

Murdoch, Australia
MacQuarie University Clinical Trial Unit
RECRUITING

Sydney, NSW 2109, Australia
Princess Alexandra Hospital
RECRUITING

Brisbane, Australia
Renji Shanghai Hospital
RECRUITING

Shanghai, 200002, China
University Hospital of Cleveland
RECRUITING

Cleveland, Ohio, 44106, United States
University of Stanford
RECRUITING

Stanford, California, 94305, United States
University of Virginia Cancer Center
RECRUITING

Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.